KDR and neoplasm: These data demonstrate that Lenvatinib exerts dual anti-angiogenic effects by simultaneously suppressing VEGF-A production in LUAD cells and inhibiting VEGFR2 activation in endothelial cells, thereby effectively disrupting the VEGF-A/VEGFR2 signalling axis and reducing tumour angiogenesis.